- For use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer
Drug | Dosing Regimen | Dose Limit/ Maximum Dose |
---|---|---|
EmcytR (estramustine) | 10-14 mg/kg PO daily in 3 or 4 divided doses | 16 mg/kg/day |
JevtanaR (cabazitaxel)* + prednisone | 25 mg/m2 IV every 3 weeks + prednisone 10 mg/day | 25 mg/m2 IV every 3 weeks + prednisone 10 mg/day |
Ketoconazole (NizoralR) | 200-400 mg PO every 8 hours | 400 mg PO every 8 hours |
mitoxantrone (NovatroneR) + prednisone | Novantrone 12 mg/m2 IV every 3 weeks + prednisone 10 mg/day | Novantrone 14 mg/m2 IV every 3 weeks + prednisone 10 mg/day |
docetaxel (TaxotereR) + prednisone | Taxotere 75 mg/m2 IV every 3 weeks + prednisone 10 mg/day | Taxotere 75 mg/m2 IV every 3 weeks + prednisone 10 mg/day |
Drug | Dosing Regimen | Authorization Limit |
---|---|---|
Zytiga | 1000 mg PO once daily in combination with prednisone 10 mg per day | Length of Benefit |
1. Zytiga. Prescribing information, Janssen Biotech, Inc. May 2015.
2. De Bono JS, et al. Abiraterone and increased survival in metastatic prostate cancer. NEJM. 2011;364(21):1995-2005.
3. Ryan CJ, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-148..
4. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: http://www.nccn.org/professionals/drug_compendium. Accessed June 30, 2015.
5. MicromedexR Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed June 30, 2015.